ArticleDiscover oncology2025
Pan-cancer analysis reveals AOC3 as a potential therapeutic biomarker for colorectal cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amine oxidase copper containing 3 (AOC3) had been reported to play an important regulatory role in the biological functional pathways, immune microenvironment and cellular function. However, the potential function of AOC3 in cancer had not been fully studied. We conducted a comprehensive analysis of the potential function of AOC3 in pan-cancer using multiple online databases and analytical methods, including mutations and differential expression analysis, pathway analysis and immune analysis. Then, the function of the AOC3 was assessed in colorectal cancer (CRC) cells. Pan-cancer analysis results show that the highest mutation frequency of ACO3 in embryonic tumor patients, in most cancers, the expression of AOC3 is significantly downregulated and the differential expression of AOC3 was mainly concentrated in CRC and female tumors. Enrichment analysis showed that AOC3 was involved in PPAR signaling pathway. In addition, bioinformatic investigation revealed a link between the AOC3 with immune cell infiltration in the tumor microenvironment. Cell experiments have confirmed that AOC3 can significantly regulate the apoptosis and cycle progression of CRC cells. In summary, our study not only comprehensively analyzed the potential mechanisms of AOC3 in pan-cancer, but also validated the potential regulatory role of AOC3 through CRC cell experiments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.